Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123511 · ClinicalTrials.gov registry record · Phase 2
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02123511: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT02123511 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02123511, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy. Side effects from radiation therapy to the head and neck, such as thickened saliva and mouth sores, may interfere with activities of daily living such as eating and drinking, and may also cause treatment to be stopped or delayed. Acetylcysteine rinse may reduce saliva thickness and mouth sores, and improve quality of life in patients with head and neck cancer undergoing radiation therapy.
Interventions
- OTHER placebo
- OTHER questionnaire administration
- OTHER quality-of-life assessment
- DRUG acetylcysteine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-04 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02123511
The ClinicalTrials.gov registry entry for NCT02123511 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT02123511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02123511 about?
NCT02123511 is a clinical study titled "Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy". This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy. Side effects from radiation therapy to the head and neck, such as thickened saliva and mouth sores, ...
What is the current status of trial NCT02123511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2014-04. Estimated completion is 2018-07-02.
What interventions are being tested in trial NCT02123511?
The interventions under investigation include: placebo (OTHER), questionnaire administration (OTHER), quality-of-life assessment (OTHER), acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT02123511?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.